Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Urol Case Rep ; 55: 102764, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38911465

RESUMO

Brucellosis, a systemic infection, can affect various organs, including the genitourinary system, causing epididymo-orchitis in 2%-20 % of cases. This report details a 34-year-old Thai male migrant worker with febrile orchitis. Initial gentamicin treatment failed, but serological tests confirmed brucellosis, likely from raw dairy consumption. The patient was successfully treated with gentamicin, doxycycline, and rifampicin, resulting in complete symptom resolution. Brucella orchitis, though rare, should be considered in patients from endemic areas. Conservative treatment with combined antibiotics is typically effective.

2.
J Microbiol Immunol Infect ; 57(1): 189-194, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37805361

RESUMO

We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.


Assuntos
Monofosfato de Adenosina/análogos & derivados , Alanina/análogos & derivados , COVID-19 , Ritonavir , Humanos , Ritonavir/uso terapêutico , Estudos Retrospectivos , Tratamento Farmacológico da COVID-19 , Anticorpos Monoclonais , Hospedeiro Imunocomprometido , Antivirais/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA